Is the Avacta share price dip a buying opportunity?

I would buy Avacta at its current share price if I was comfortable with the risk inherent in its developmental drug pipeline. So, am I?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At 130p, the Avacta (LSE: AVCT) share price is well below its May 2021 price of 269p. Avacta had rallied strongly from a low of 16p, reached during the March 2020 coronavirus market crash. Looking further back and the Avacta share price history looks exactly as I would expect from a chronically early-stage biotechnology company: some ups but mainly downs.

Created with Highcharts 11.4.3Avacta Group Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Ultimately, the success or failure of Avacta’s developmental pipeline will determine where its share price goes in the future. And it is that pipeline that will determine whether or not I should buy Avacta at its current share price.

No news is good news

There has not been any recent news about the pipeline. But the company did reveal that it had no banking relationship with either Silicon Valley Bank (SVB) or its UK subsidiary on Monday. It had no cash on deposit, nor was it reliant on SVB for funding. That is good news. Looking further back and Avacta raised some equity in February and January. It also released some positive news from the phase one clinical trial of one of its drugs.

Should you invest £1,000 in Johnson Matthey Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Johnson Matthey Plc made the list?

See the 6 stocks

Getting a drug from the lab bench to market is usually transformational for a pharmaceutical and biotechnology company like Avacta. Right now the company has one therapy, AVA6000, in phase one clinical trials. It is AVA6000 that investors will be looking at closely.

Moving from phases one to two, and two to three, will gain their interest. Completing phase three will get their attention. So how likely is it that AVA6000 — a modified form of the generic chemotherapy doxorubicin — moves through the phases?

I like to start with a base rate for success. According to one report, only 5.4% of developmental oncology drugs made the jump from phase one all the way to approval. Now, AVA6000 was granted Orphan Drug Designation from the US FDA in September 2022. That means it has been identified as a potential treatment for rare diseases. The success rate for drugs for rare diseases is higher at 17%.

Avacta share price

Until it can command meaningful revenue, Avacta will continue to turn to investors and creditors for cash. Even if AVA6000 makes it through to approval, that takes 10.5 years on average. If the drug ends up licenced for the treatment of a rare disease, then revenues might be disappointing. Of course, Avacta has other drugs in its pipeline, but the same calculus has to be applied if they move to phase one trials.

Drug development companies are risky. More often than not the development fails. Successes take time and a lot of funding, and sometimes do not make attractive returns. I don’t think Avacta, at its current share price, is a buying opportunity for me. Here is why.

I would not invest in a single developmental pharmaceutical company. Because the chances of individual success are low, a basket of them makes more sense. Even then that would be as part of a larger diversified stock portfolio. The hope would be that at least one succeeds to make up for the failures of the others. But I have learnt through experience that I am not comfortable with the risk inherent in stocks like Avacta. That’s true even if I held a bunch of them.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Johnson Matthey Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Johnson Matthey Plc made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James McCombie has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »

a couple embrace in front of their new home
Investing Articles

Prediction: in 1 year, the Taylor Wimpey share price could reach…

Can Britain’s reformed planning scheme send the Taylor Wimpey share price into overdrive? Here’s what the latest analyst forecasts predict.

Read more »